Invesco S&P 500 Equal Weight Health Care ETF(RSPH.US)

Company Encyclopedia
View More
name
Invesco S&P 500 Equal Weight Health Care ETF
RSPH.US
News
View More

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

Eli Lilly's recent study shows that combining Taltz and Zepbound significantly improves symptoms of psoriatic arthritis and aids in weight loss, outperforming Taltz alone. In a Phase 3b trial, 31.7% of patients on the dual treatment achieved a 50% improvement in PsA activity and a weight reduction of at least 10%. The study is the first to evaluate an incretin therapy with a PsA biologic. Adverse events were generally mild. Eli Lilly shares rose 0.72% to $1093.00, nearing a 52-week high.

benzinga_article·
US
LLY
-1.99%
benzinga_article·
US
LLY
-1.99%

Deals of the day-Mergers and acquisitions

On January 9, Aon announced its acquisition of an insurance broker license in Japan and the establishment of a new corporate broking division. Rio Tinto is in preliminary discussions to acquire Glencore, potentially forming the largest mining company with a market value of approximately $207 billion. Additionally, Merck is reportedly negotiating to purchase Revolution Medicines for between $28 billion and $32 billion, according to the Financial Times.

Reuters·
US
RVMD
+10.48%
US
AON
-0.33%
US
MRK
-0.41%
Reuters·
US
RVMD
+10.48%
US
AON
-0.33%
US
MRK
-0.41%

Trending | MRNA Plummets 5% on Thursday, Some Put options Soar 350%

On January 8, Eastern Time, Moderna options saw a total of 122203 contracts traded, with calls accounting for 59% and puts making up 40%.

LB Option·
US
MRNA
+1.30%
LB Option·
US
MRNA
+1.30%

Molina Healthcare Inc. Stock Outperforms Competitors On Strong Trading Day

Molina Healthcare Inc. (MOH) shares rose 4.04% to $183.50 on a strong trading day, outperforming competitors like Humana Inc. (HUM) and Centene Corp. (CNC). The S&P 500 Index increased by 0.01%, while the Dow Jones Industrial Average rose 0.55%. Despite the gains, Molina's stock remains 49.02% below its 52-week high of $359.97 reached on April 4th. Trading volume was 1.7 million, matching its 50-day average.

Dow Jones·
US
MOH
-1.09%
Dow Jones·
US
MOH
-1.09%

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $820.00 Price Target at Truist Financial

Truist Financial has raised its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) from $798.00 to $820.00, maintaining a "buy" rating. This suggests a potential upside of 0.76% from the current price. Other analysts have also adjusted their targets, with Royal Bank of Canada setting it at $708.00 and UBS at $660.00. Regeneron recently reported earnings of $11.83 per share, exceeding expectations. The stock is currently trading at $813.78, with a market cap of $85.53 billion and a PE ratio of 19.49.

Market Beat·
US
REGN
-0.56%
Market Beat·
US
REGN
-0.56%
© 2026 Longbridge｜Disclaimer